(Bloomberg View) — As young doctors in the 1980s, we witnessed the devastation of the AIDS epidemic. In those early years, patients died within months of diagnosis, often in agony, suffering headaches, diarrhea, shortness of breath and even blindness. Yet medical science fought back — first identifying the virus, then developing a diagnostic test and coming up with treatments. By 1996, highly effective therapy was available. While much work remains, in particular the development of an HIV vaccine, the response to AIDS stands as a success story in the history of medicine.
At a time when federal funding for medical research faces deep cuts, it’s important to remember especially one key part of this story — the part that took place well before AIDS was ever discovered in people. The fact is, progress against AIDS did not come from maximizing therapeutic options that were available in 1985. HIV-infected patients did not do better because they were given clean bed sheets, better social care or drugs already available at the time. The breakthroughs came in the form of new medicines that grew out of fundamental research carried out decades earlier.
(Related on ThinkAdvisor: 5 ways scientists could supercharge long-term care insurance)
Back in the 1960s and ’70s, scientists studied retroviruses that caused cancer in animals, but weren’t associated with human disease. They discovered that these viruses produce a long protein and that, for the viruses to successfully replicate in cells, this protein needs to be cut into smaller pieces by an enzyme known as a protease. The researchers figured out that interfering with the protease kills the virus. And AIDS researchers in the 1980s and ’90s built on this knowledge to create extremely effective antiviral drugs known as protease inhibitors.